Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Evolut Low Risk is a large, prospective trial that initially enrolled 1,478 patients at 86 centers in the United States, Canada, Europe, Japan, Australia and New Zealand to compare the safety and ...

“The delta in favor of Evolut at 2 years is 1.1. The delta in favor of Evolut at 5 years is 2.1. This widening of the curve in favor of TAVR, even though it’s not statistically ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, ...

The company’s structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences’s SAPIEN TAVR product.